Health Canada approves clinical trial for ToeFX Light Therapy Device

clinical-trial-approved

ToeFX Inc., a Canadian medical device company developing a novel photodynamic therapy for onychomycosis, announced today that it has received Investigational Testing Approval (ITA) from Health Canada. Under the ITA, the company is authorized to begin clinical trials of the ToeFX Light Therapy device in Hamilton, Ontario. Trials are expected to begin in early 2020. The trial’s principal investigator is Dr. Alexander Rabinovich, MD, FRCSC, an orthopaedic surgeon and Assistant Clinical Professor (Adjunct) at McMaster University. Patients may take the online screening questionnaire HERE

Read More

ToeFX receives $30,000 grant for lab studies

ToeFX technology research

ToeFX received a Voucher for Innovation and Productivity (VIP) grant from the Ontario Centres of Excellence.  These grants help companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario’s industry and publicly funded post-secondary institutions. Working with researchers at McMaster University, ToeFX has successfully concluded ex vivo trials of its flagship product.  The ex vivo trials were conducted using ToeFX’s photodynamic therapy treatment, comprising a propriety formulation and custom light source.

Read More